dataesr/scientific-paragraphs-categorization huggingface dataset:
gov/search?id=%22NCT00036855%22 CHEMBL1201606 IBRITUMOMAB TIUXETAN Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0019465 nodal marginal zone B-cell lymphoma 1 Completed https://clinicaltrials. gov/search?id=%22NCT00438880%22 CHEMBL2109330 IC14 Antibody Monocyte differentiation antigen CD14 inhibitor Inhibitor EFO_0005547 dengue disease 2 Withdrawn https://clinicaltrials. gov/search?id=%22NCT03875560%22 CHEMBL2109330 IC14 Antibody Monocyte differentiation antigen CD14 inhibitor Inhibitor EFO_1000637 acute respiratory distress syndrome 2 Withdrawn https://clinicaltrials. gov/search?id=%22NCT03017547%22 CHEMBL2109330 IC14 Antibody Monocyte differentiation antigen CD14 inhibitor Inhibitor MONDO_0100096 COVID-19 2 Recruiting https://clinicaltrials. gov/search?id=%22NCT04488081%22 CHEMBL2109330 IC14 Antibody Monocyte differentiation antigen CD14 inhibitor Inhibitor MONDO_0100130 adult acute respiratory distress syndrome 2 Terminated https://clinicaltrials.
gov/search?id=%22NCT00233207%22 CHEMBL2109330 IC14 Antibody Monocyte differentiation antigen CD14 inhibitor Inhibitor EFO_0000253 amyotrophic lateral sclerosis 1 Completed https://clinicaltrials. gov/search?id=%22NCT03487263%22 CHEMBL2109389 IMGATUZUMAB Antibody Low affinity immunoglobulin gamma Fc region receptor III-A cross-linking agent Cross-linking agent EFO_1001951 colorectal carcinoma 2 Completed https://clinicaltrials. gov/search?id=%22NCT01326000%22 CHEMBL2109389 IMGATUZUMAB Antibody Low affinity immunoglobulin gamma Fc region receptor III-A cross-linking agent Cross-linking agent EFO_0000616 neoplasm 1 Completed https://clinicaltrials. gov/search?id=%22NCT00721266%22 CHEMBL2109389 IMGATUZUMAB Antibody Low affinity immunoglobulin gamma Fc region receptor III-A cross-linking agent Cross-linking agent EFO_0003060 non-small cell lung carcinoma 1 Withdrawn https://clinicaltrials.
gov/search?id=%22NCT01702714%22 CHEMBL2109389 IMGATUZUMAB Antibody Low affinity immunoglobulin gamma Fc region receptor III-A cross-linking agent Cross-linking agent EFO_0006859 head and neck malignant neoplasia 1 Completed https://clinicaltrials. gov/search?id=%22NCT01046266%22 CHEMBL2109334 INEBILIZUMAB Antibody B-lymphocyte antigen CD19 binding agent Binding agent EFO_0000540 immune system disease 4 http://www. whocc. no/atc_ddd_index/?code=L04AA47 CHEMBL2109334 INEBILIZUMAB Antibody B-lymphocyte antigen CD19 binding agent Binding agent EFO_0004991 Myasthenia gravis 3 Recruiting https://clinicaltrials. gov/search?id=%22NCT04524273%22 CHEMBL2109334 INEBILIZUMAB Antibody B-lymphocyte antigen CD19 binding agent Binding agent MONDO_0017287 IgG4-related disease 3 Recruiting https://clinicaltrials.
gov/search?id=%22NCT04540497%22 CHEMBL2109334 INEBILIZUMAB Antibody B-lymphocyte antigen CD19 binding agent Binding agent EFO_0000095 chronic lymphocytic leukemia 2 Completed https://clinicaltrials. gov/search?id=%22NCT01466153%22 CHEMBL2109334 INEBILIZUMAB Antibody B-lymphocyte antigen CD19 binding agent Binding agent EFO_0000403 diffuse large B-cell lymphoma 2 Completed https://clinicaltrials. gov/search?id=%22NCT01453205%22 CHEMBL2109334 INEBILIZUMAB Antibody B-lymphocyte antigen CD19 binding agent Binding agent EFO_0004256 neuromyelitis optica 2 Completed https://clinicaltrials. gov/search?id=%22NCT02200770%22 CHEMBL2109334 INEBILIZUMAB Antibody B-lymphocyte antigen CD19 binding agent Binding agent EFO_0007332 Japanese encephalitis 2 Not yet recruiting https://clinicaltrials. gov/search?id=%22NCT04372615%22 CHEMBL2109334 INEBILIZUMAB Antibody B-lymphocyte antigen CD19 binding agent Binding agent EFO_0000311 cancer 1 Completed https://clinicaltrials.
gov/search?id=%22NCT00983619%22,https://clinicaltrials. gov/search?id=%22N CHEMBL2109334 INEBILIZUMAB Antibody B-lymphocyte antigen CD19 binding agent Binding agent EFO_0000574 lymphoma 1 Completed https://clinicaltrials. gov/search?id=%22NCT02271945%22 CHEMBL2109334 INEBILIZUMAB Antibody B-lymphocyte antigen CD19 binding agent Binding agent EFO_0001642 lymphoid neoplasm 1 Completed https://clinicaltrials. gov/search?id=%22NCT01957579%22 CHEMBL2109334 INEBILIZUMAB Antibody B-lymphocyte antigen CD19 binding agent Binding agent EFO_0003885 multiple sclerosis 1 Completed https://clinicaltrials. gov/search?id=%22NCT01585766%22 CHEMBL2109334 INEBILIZUMAB Antibody B-lymphocyte antigen CD19 binding agent Binding agent EFO_1001993 scleroderma 1 Completed https://clinicaltrials. gov/search?id=%22NCT00946699%22 CHEMBL2109334 INEBILIZUMAB Antibody B-lymphocyte antigen CD19 binding agent Binding agent EFO_0001378 multiple myeloma 0 Completed https://clinicaltrials.
gov/search?id=%22NCT01861340%22 CHEMBL2108508 INTERFERON ALFA-2A Protein Interferon alpha/beta receptor agonist Agonist EFO_0000220 acute lymphoblastic leukemia 3 Completed https://clinicaltrials. gov/search?id=%22NCT00483132%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent HP_0012664 Reduced ejection fraction 2 Not yet recruiting https://clinicaltrials. gov/search?id=%22NCT03332888%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0000870 childhood acute lymphoblastic leukemia 2 Completed https://clinicaltrials. gov/search?id=%22NCT00057811%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0001549 hemolytic-uremic syndrome 2 Unknown status https://clinicaltrials.
gov/search?id=%22NCT00531089%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0003541 adult acute lymphoblastic leukemia 2 Withdrawn https://clinicaltrials. gov/search?id=%22NCT02538926%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0004695 liver lymphoma 2 Recruiting https://clinicaltrials. gov/search?id=%22NCT04115631%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0009348 classic Hodgkin lymphoma 2 Completed https://clinicaltrials. gov/search?id=%22NCT00654732%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0018170 idiopathic nephrotic syndrome 2 Completed https://clinicaltrials. gov/search?id=%22NCT01268033%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0019139 acquired hemophilia 2 Unknown status https://clinicaltrials.
gov/search?id=%22NCT03700229%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0020743 mixed phenotype acute leukemia 2 Recruiting https://clinicaltrials. gov/search?id=%22NCT02135874%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0021117 lung neoplasm 2 Completed https://clinicaltrials. gov/search?id=%22NCT00001805%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0044917 T-lymphoblastic lymphoma 2 Withdrawn https://clinicaltrials. gov/search?id=%22NCT02538926%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent Orphanet_232 Sickle cell anemia 2 Terminated https://clinicaltrials. gov/search?id=%22NCT01279616%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent Orphanet_238510 Lymphoproliferative syndrome 2 Terminated https://clinicaltrials.
gov/search?id=%22NCT00869323%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent Orphanet_797 Sarcoidosis 2 Completed https://clinicaltrials. gov/search?id=%22NCT00855205%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent Orphanet_98878 Hemophilia A 2 Completed https://clinicaltrials. gov/search?id=%22NCT00331006%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000096 neoplasm of mature B-cells 1 Suspended https://clinicaltrials. gov/search?id=%22NCT04607772%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000183 Hodgkins lymphoma 1 Withdrawn https://clinicaltrials. gov/search?id=%22NCT02408042%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000191 MALT lymphoma 1 Terminated https://clinicaltrials.
gov/search?id=%22NCT00012298%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000198 myelodysplastic syndrome 1 Active, not recruiting https://clinicaltrials. gov/search?id=%22NCT02960646%22,https://clinicaltrials. gov/search?id=%22N CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000209 T-cell acute lymphoblastic leukemia 1 Recruiting https://clinicaltrials. gov/search?id=%22NCT03808610%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000220 acute lymphoblastic leukemia 1 Recruiting https://clinicaltrials. gov/search?id=%22NCT01371630%22,https://clinicaltrials. gov/search?id=%22N CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000222 acute myeloid leukemia 1 Completed https://clinicaltrials.
gov/search?id=%22NCT02779283%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000304 breast adenocarcinoma 1 Suspended https://clinicaltrials. gov/search?id=%22NCT03432741%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000309 Burkitts lymphoma 1 Completed https://clinicaltrials. gov/search?id=%22NCT01397825%22,https://clinicaltrials. gov/search?id=%22N CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000311 cancer 1 Active, not recruiting https://clinicaltrials. gov/search?id=%22NCT00788684%22,https://clinicaltrials. gov/search?id=%22N CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000339 chronic myelogenous leukemia 1 Active, not recruiting https://clinicaltrials.
gov/search?id=%22NCT01619761%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000384 Crohn's disease 1 Recruiting https://clinicaltrials. gov/search?id=%22NCT00692939%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000565 leukemia 1 Recruiting https://clinicaltrials. gov/search?id=%22NCT02356159%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000616 neoplasm 1 Recruiting https://clinicaltrials. gov/search?id=%22NCT03783403%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000685 rheumatoid arthritis 1 Terminated https://clinicaltrials. gov/search?id=%22NCT03061838%22,https://clinicaltrials. gov/search?id=%22N CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000692 schizophrenia 1 Recruiting https://clinicaltrials.
gov/search?id=%22NCT03983018%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000699 Sjogren syndrome 1 Completed https://clinicaltrials. gov/search?id=%22NCT00101829%22,https://clinicaltrials. gov/search?id=%22N CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000707 squamous cell carcinoma 1 Completed https://clinicaltrials. gov/search?id=%22NCT04361409%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000768 idiopathic pulmonary fibrosis 1 Completed https://clinicaltrials. gov/search?id=%22NCT01266317%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0001359 type I diabetes mellitus 1 Unknown status https://clinicaltrials.
gov/search?id=%22NCT00798785%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0001378 multiple myeloma 1 Terminated https://clinicaltrials. gov/search?id=%22NCT00176475%22,https://clinicaltrials. gov/search?id=%22N CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0001423 encephalomyelitis 1 Completed https://clinicaltrials. gov/search?id=%22NCT00259805%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0001642 lymphoid neoplasm 1 Terminated https://clinicaltrials. gov/search?id=%22NCT01596127%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0002508 Parkinson's disease 1 Recruiting https://clinicaltrials. gov/search?id=%22NCT04127578%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0002617 metastatic melanoma 1 Terminated https://clinicaltrials.
gov/search?id=%22NCT01032122%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0002690 systemic lupus erythematosus 1 Completed https://clinicaltrials. gov/search?id=%22NCT00036491%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0003778 psoriatic arthritis 1 Completed https://clinicaltrials. gov/search?id=%22NCT00509678%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0003884 chronic kidney disease 1 Completed https://clinicaltrials. gov/search?id=%22NCT01178216%22,https://clinicaltrials. gov/search?id=%22N CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0003885 multiple sclerosis 1 Terminated https://clinicaltrials.
gov/search?id=%22NCT01212094%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0004145 myopathy 1 Terminated https://clinicaltrials. gov/search?id=%22NCT00278564%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0004236 focal segmental glomerulosclerosis 1 Recruiting https://clinicaltrials. gov/search?id=%22NCT03763643%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0004256 neuromyelitis optica 1 Completed https://clinicaltrials. gov/search?id=%22NCT00787722%22,https://clinicaltrials. gov/search?id=%22N CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0004289 lymphoid leukemia 1 Completed https://clinicaltrials. gov/search?id=%22NCT00366418%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0004991 Myasthenia gravis 1 Completed https://clinicaltrials.
gov/search?id=%22NCT00619671%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0005140 autoimmune disease 1 Completed https://clinicaltrials. gov/search?id=%22NCT01086631%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0005297 Granulomatosis with Polyangiitis 1 Completed https://clinicaltrials. gov/search?id=%22NCT00072592%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0005531 urticaria 1 Terminated https://clinicaltrials. gov/search?id=%22NCT00216762%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0005952 non-Hodgkins lymphoma 1 Recruiting https://clinicaltrials. gov/search?id=%22NCT04673617%22,https://clinicaltrials.
gov/search?id=%22N CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0007160 autoimmune thrombocytopenic purpura 1 Completed https://clinicaltrials. gov/search?id=%22NCT01713738%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0007187 bullous pemphigoid 1 Completed https://clinicaltrials. gov/search?id=%22NCT00286325%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0007498 Stiff-Person syndrome 1 Terminated https://clinicaltrials. gov/search?id=%22NCT02282514%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0008520 primary progressive multiple sclerosis 1 Completed https://clinicaltrials. gov/search?id=%22NCT02253264%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0008522 secondary progressive multiple sclerosis 1 Completed https://clinicaltrials.
gov/search?id=%22NCT02253264%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0008610 ocular cicatricial pemphigoid 1 Completed https://clinicaltrials. gov/search?id=%22NCT00584935%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0009606 macular degeneration 1 Completed https://clinicaltrials. gov/search?id=%22NCT02332941%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_1000131 Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive 1 Active, not recruiting https://clinicaltrials. gov/search?id=%22NCT02960646%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_1000550 Splenic Marginal Zone Lymphoma 1 Completed https://clinicaltrials.
gov/search?id=%22NCT00438880%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_1000956 hairy cell leukemia 1 Recruiting https://clinicaltrials. gov/search?id=%22NCT03805932%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_1001051 mycosis fungoides 1 Suspended https://clinicaltrials. gov/search?id=%22NCT03432741%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_1001365 Lymphoma, AIDS-Related 1 Terminated https://clinicaltrials. gov/search?id=%22NCT00036855%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_1001383 Opsoclonus-Myoclonus Syndrome 1 Completed https://clinicaltrials. gov/search?id=%22NCT00244361%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_1001466 Graves ophthalmopathy 1 Completed https://clinicaltrials.
gov/search?id=%22NCT00150111%22,https://clinicaltrials. gov/search?id=%22N CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_1001486 primary biliary cirrhosis 1 Completed https://clinicaltrials. gov/search?id=%22NCT00364819%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_1001779 chronic myelomonocytic leukemia 1 Active, not recruiting https://clinicaltrials. gov/search?id=%22NCT02960646%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_1002048 kidney failure 1 Not yet recruiting https://clinicaltrials. gov/search?id=%22NCT04540380%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent HP_0001871 Abnormality of blood and blood-forming tissues 1 Not yet recruiting https://clinicaltrials.
gov/search?id=%22NCT04243434%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent HP_0001915 Aplastic anemia 1 Active, not recruiting https://clinicaltrials. gov/search?id=%22NCT02960646%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0000873 lymphoblastic lymphoma 1 Active, not recruiting https://clinicaltrials. gov/search?id=%22NCT02960646%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0001023 prolymphocytic leukemia 1 Active, not recruiting https://clinicaltrials. gov/search?id=%22NCT02296918%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0001437 pulmonary alveolar proteinosis 1 Completed https://clinicaltrials.
gov/search?id=%22NCT01842386%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0001718 scleritis 1 Completed https://clinicaltrials. gov/search?id=%22NCT00415506%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0002083 Richter syndrome 1 Completed https://clinicaltrials. gov/search?id=%22NCT00472849%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0002334 hematopoietic and lymphoid system neoplasm 1 Recruiting https://clinicaltrials. gov/search?id=%22NCT04022239%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0002462 glomerulonephritis 1 Completed https://clinicaltrials. gov/search?id=%22NCT00275613%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0004095 B-cell neoplasm 1 Recruiting https://clinicaltrials.
gov/search?id=%22NCT02911142%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0013730 graft versus host disease 1 Recruiting https://clinicaltrials. gov/search?id=%22NCT03689894%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0015564 Castleman disease 1 Withdrawn https://clinicaltrials. gov/search?id=%22NCT02228512%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0015760 T-cell non-Hodgkin lymphoma 1 Recruiting https://clinicaltrials. gov/search?id=%22NCT01701986%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0018896 thrombotic thrombocytopenic purpura 1 Withdrawn https://clinicaltrials. gov/search?id=%22NCT00251277%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0019088 post-transplant lymphoproliferative disease 1 Terminated https://clinicaltrials.
gov/search?id=%22NCT00036855%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0019457 therapy related acute myeloid leukemia and myelodysplastic syndrome 1 Active, not recruiting https://clinicaltrials. gov/search?id=%22NCT01619761%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0019465 nodal marginal zone B-cell lymphoma 1 Terminated https://clinicaltrials. gov/search?id=%22NCT00012298%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0024880 metastatic malignant neoplasm 1 Terminated https://clinicaltrials. gov/search?id=%22NCT01596127%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0044881 hematopoietic and lymphoid cell neoplasm 1 Active, not recruiting https://clinicaltrials.
gov/search?id=%22NCT02367196%22,https://clinicaltrials. gov/search?id=%22N CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0044887 central nervous system non-hodgkin lymphoma 1 Recruiting https://clinicaltrials. gov/search?id=%22NCT02315326%22,https://clinicaltrials. gov/search?id=%22N CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent MONDO_0044889 high grade B-cell lymphoma 1 Active, not recruiting https://clinicaltrials. gov/search?id=%22NCT03742258%22,https://clinicaltrials. gov/search?id=%22N CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent Orphanet_1334 Chronic mucocutaneous candidosis 1 Completed https://clinicaltrials. gov/search?id=%22NCT01842386%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent Orphanet_282 Frontotemporal dementia 1 Recruiting https://clinicaltrials.
gov/search?id=%22NCT04408625%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent Orphanet_309144 Gangliosidosis 1 Recruiting https://clinicaltrials. gov/search?id=%22NCT03952637%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent Orphanet_365 Glycogen storage disease due to acid maltase deficiency 1 Active, not recruiting https://clinicaltrials. gov/search?id=%22NCT02240407%22 CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent Orphanet_84 Fanconi anemia 1 Not yet recruiting https://clinicaltrials. gov/search?id=%22NCT04784052%22.